Cyngn (CYN) 10-K 24 Mar 22 2021 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 24, 2022	Jun. 30, 2021
Document Information Line Items
Entity Registrant Name	CYNGN INC.
Trading Symbol	CYN
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		27,094,430
Entity Public Float			$ 53,013,438
Amendment Flag	false
Entity Central Index Key	0001874097
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-40932
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-2007094
Entity Address, Address Line One	1015 O’Brien Dr
Entity Address, City or Town	Menlo Park
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94025
City Area Code	(650)
Local Phone Number	924-5905
Title of 12(b) Security	Common Stock, Par Value $0.00001
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Name	Marcum LLP
Auditor Location	San Jose, California
Auditor Firm ID	688

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 21,945,981	$ 6,056,190
Restricted cash	50,000	400,000
Prepaid expenses and other current assets	525,304	48,852
Total current assets	22,521,285	6,505,042
Property and equipment, net	102,787	133,805
Intangible assets, net	30,917	34,383
Total Assets	22,654,989	6,673,230
Current liabilities
Accounts payable	112,271	73,016
Accrued expenses and other current liabilities	295,156	307,402
Total current liabilities	407,427	380,418
Note payable, Paycheck Protection Program		695,078
Total liabilities	407,427	1,075,496
Commitments and contingencies (Note 12)
Stockholders’ Equity
Convertible Series A, B and C preferred stock, Par $0.00001; 10,000,000 authorized as of December 31, 2021 and 21,982,491 shares authorized, issued and outstanding as of December 31, 2020		220
Common stock, Par $0.00001; 100,000,000 shares authorized, 26,487,680 shares issued and outstanding as of December 31, 2021 and 42,000,000 shares authorized, 951,794 shares issued and outstanding as of December 31, 2020	265	10
Common stock warrants	170,397
Additional paid-in capital	138,570,430	114,291,505
Accumulated deficit	(116,493,530)	(108,694,001)
Total stockholders’ equity	22,247,562	5,597,734
Total Liabilities and Stockholders’ Equity	$ 22,654,989	$ 6,673,230

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	100,000,000	42,000,000
Common stock, shares issued	26,487,680	951,794
Common stock, shares outstanding	26,487,680	951,794
Convertible Series A Preferred Stock
Convertible preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	10,000,000	21,982,491
Convertible preferred stock, shares issued		21,982,491
Convertible preferred stock, shares outstanding		21,982,491
Convertible Series B Preferred Stock
Convertible preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	10,000,000	21,982,491
Convertible preferred stock, shares issued		21,982,491
Convertible preferred stock, shares outstanding		21,982,491
Convertible Series C Preferred Stock
Convertible preferred stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Convertible preferred stock, shares authorized	10,000,000	21,982,491
Convertible preferred stock, shares issued		21,982,491
Convertible preferred stock, shares outstanding		21,982,491

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue
Research and development	4,990,407	5,120,979
General and administrative	4,409,651	3,252,649
Total operating expenses	9,400,058	8,373,628
Loss from operations	(9,400,058)	(8,373,628)
Interest (expense) income	(9,580)	39,841
Other (expense) income	7,173	(5,020)
Paycheck Protection Program Note forgiveness	1,602,936
Total other income, net	1,600,529	34,821
Net loss	$ (7,799,529)	$ (8,338,807)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (1.33)	$ (8.78)
Weighted-average shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)	5,861,730	949,544

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity - USD ($)	Convertible Preferred Stock	Common Stock	Common Stock Warrants	Additional Paid in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2019	$ 220	$ 10		$ 114,159,150	$ (100,355,194)	$ 13,804,186
Balance (in Shares) at Dec. 31, 2019	21,982,491	949,086
Exercise of stock options				623		623
Exercise of stock options (in Shares)		2,708
Stock-based compensation				131,732		131,732
Net loss					(8,338,807)	(8,338,807)
Balance at Dec. 31, 2020	$ 220	$ 10		114,291,505	(108,694,001)	5,597,734
Balance (in Shares) at Dec. 31, 2020	21,982,491	951,794
Exercise of stock options				14,220		$ 14,220
Exercise of stock options (in Shares)		53,395				109,902
Issuance of common stock in connection with initial public offering, net of closing costs of $2,954,110		$ 35		23,295,855		$ 23,295,890
Issuance of common stock in connection with initial public offering, net of closing costs of $2,954,110 (in Shares)		3,500,000
Conversion of convertible preferred stock to common stock in connection with initial public offering	$ (220)	$ 220
Conversion of convertible preferred stock to common stock in connection with initial public offering (in Shares)	(21,982,491)	21,982,491
Stock-based compensation				1,139,247		1,139,247
Issuance of warrants			170,397	(170,397)
Net loss					(7,799,529)	(7,799,529)
Balance at Dec. 31, 2021		$ 265	$ 170,397	$ 138,570,430	$ (116,493,530)	$ 22,247,562
Balance (in Shares) at Dec. 31, 2021		26,487,680

Consolidated Statements of St_2

Consolidated Statements of Stockholders’ Equity (Parentheticals)	12 Months Ended
	Dec. 31, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Iinitial public offering, net of closing costs	$ 2,954,110

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (7,799,529)	$ (8,338,807)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	85,855	159,040
Stock-based compensation	1,139,247	131,732
Gain on disposal of asset	(31,356)
Gain on forgiveness of Paycheck Protection Program Notes	(1,602,936)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(476,452)	33,774
Accounts payable	39,255	(43,335)
Accrued expenses and other current liabilities	3,496	137,535
Net cash used in operating activities	(8,642,419)	(7,920,061)
Cash flows from investing activities
Purchase of property and equipment	(62,204)
Disposal of assets	42,189
Net cash used in investing activities	(20,015)
Cash flows from financing activities
Proceeds from issuance of common stock upon initial public offering, net of offering costs	23,295,890
Proceeds from Paycheck Protection Program Notes	892,115	695,078
Proceeds from exercise of stock options	14,220	623
Net cash provided by financing activities	24,202,225	695,701
Net increase/(decrease) in cash and cash equivalents and restricted cash	15,539,791	(7,224,360)
Cash and cash equivalents and restricted cash, beginning of year	6,456,190	13,680,550
Cash and cash equivalents and restricted cash, end of year	21,995,981	6,456,190
Supplemental disclosure of cash flow:
Cash paid during the year for taxes	16,719	$ 10,813
Supplemental disclosure of non-cash financing activities:
The Company’s Paycheck Protection Program Note was forgiven by the SBA in the amount of $1,602,936.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parentheticals) - USD ($) $ in Billions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Cash Flows [Abstract]
Paycheck protection program note was forgiven by the SBA in the amount	$ 1,602,936	$ 1,602,936

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business	1. Description of Business Headquartered in Menlo Park, California, CYNGN Inc., together with its subsidiaries (collectively, “Cyngn” or the “Company”), was incorporated in Delaware in 2013. Cyngn Singapore PTE. LTD., a Singaporean limited company organized in 2015 and Cyngn Philippines, Inc., a Philippine corporation incorporated in 2018 are wholly owned subsidiaries. The Company is in the process of dissolving these subsidiaries. Cyngn develops autonomous driving software that can be deployed on multiple vehicle types in various environments. The Company has been operating autonomous vehicles (“AV”) in production environments since 16 Built and tested in difficult and diverse real-world environments, the self-driving system (DriveMod), fleet management system, and Software Development Kit combine to create a full-stack advanced autonomy solution designed to be modular, extendable, and safe. The Company operates one business segment. Initial Public Offering On October 22, 2021, the Company closed the initial public offering (the “IPO”) of 3,500,000 shares of its authorized common stock at an offering price of $7.50 per share. Simultaneous with the closing of the IPO, the common stock began trading on the NASDAQ Capital Market under the symbol “CYN.” The IPO generated net proceeds of $23.3 million after deducting underwriting discounts, commissions and offering expenses. The Company also granted its underwriters the election to exercise a 45-day over-allotment option to purchase an additional 525,000 shares of common stock at the IPO offering price, less underwriting discounts. The underwriters elected not to exercise the over-allotment option in whole or in part. No price stabilization activities have been carried out since the IPO, and due to the stock’s share price performance, the underwriters have, as stabilizing manager on behalf of the Company, decided to end the stock trading stabilization period. Simultaneous with the closing of its IPO, the Company also issued 140,000 warrants (the “Warrant”) to its underwriters. Each Warrant entitles its holder the option to purchase at a future exercise date, one share of common stock at an initial exercise price of $9.375 per share, subject to certain adjustments and restrictions relating to subsequent resale and transfers. The Purchase Warrants are exercisable six (6) months after the IPO and expire five (5) years thereafter. At the completion of the IPO, all shares of the Company’s outstanding convertible preferred stock shares automatically converted to shares of common stock (see Note 7. Capital Structure). Immediately after the IPO, the Company filed an amended and restated certificate of incorporation, which became effective on October 22, 2021. The amended and restated certificate of incorporation authorized 110,000,000 shares consisting of 100,000,000 shares of common stock, at a par value of $0.00001, and 10,000,000 shares of preferred stock at a par value of $0.00001. The rights of the holders of common stock are subject to and qualified by rights of the holders of the preferred stock. Additionally, the Company recognized $1.1 million of stock-based compensation expense related to stock options granted to employees with time-based vesting conditions. Liquidity The Company has incurred losses from operations since inception. The Company incurred net losses of $7.8 million and $8.3 million for the year ended December 31, 2021 and 2020, respectively. Accumulated deficit amounted to $116.5 million and $108.7 million as of December 31, 2021 and 2020, respectively. Net cash used in operating activities was $8.6 million and $7.9 million for the year ended December 31, 2021 and 2020, respectively. The Company’s liquidity is based on its ability to enhance its operating cash flow position, obtain capital financing from equity interest investors and obtain funds from outside sources of financing to fund its general operations, research and development activities and capital expenditures. The Company’s ability to continue as a going concern is dependent on management’s ability to successfully execute its business plan, which includes generating progressive revenue streams while controlling operating costs and expenses, to then result in positive operating cash flows. The Company’s unrestricted balance of cash and cash equivalents was $21.9 million and $6.1 million as of December 31, 2021 and 2020, respectively. Based on cash flow projections from operating and financing activities and existing balances of cash and cash equivalents, management is of the opinion that the Company has sufficient funds for sustainable operations and it will be able to meet its payment obligations and commitments from operations for at least one year from the issuance date of this report. Based on the above considerations, the Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and liquidation of liabilities during the normal course of operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements as of and for the years ended December 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include all normal adjustments necessary for a fair presentation of the Company’s financial position at December 31, 2021 and 2020, and operating results and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the following: i) audited consolidated financial statements as of and for the years ended December 31, 2020 and 2019; ii) the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and’ iii) our final prospectus (the “Prospectus”), filed with the Securities and Exchange Commission or the SEC, pursuant to Rule 424(b) under the Securities Act of 1933, as amended or the Securities Act), on October 21, 2021. Principles of Consolidation The consolidated financial statements include the accounts of CYNGN Inc. and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated upon consolidation. Foreign Currency Translation The functional and reporting currency for Cyngn is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than U.S. dollar are translated into the U.S. dollar at period end rates, income and expenses are translated at the weighted average exchange rates for the period and equity is translated at the historical exchange rates. Foreign currency translation adjustments and transactional gains and losses are immaterial to the consolidated financial statements. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to underwriter’s warrants and share-based compensation. Estimates are based on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company’s cash is placed with high-credit-quality financial institutions and at times exceeds federally insured limits. The Company has not experienced any credit loss relating to its cash equivalents. Concentration of Supplier Risk The Company generally utilizes suppliers for outside development and engineering support. The Company does not believe that there is any significant supplier concentration risk as of December 31, 2021 and 2020. Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid money market placements with a remaining maturity of three months or less to be cash equivalents. The Company had $21.9 million and $6.1 million of unrestricted cash and cash equivalents as of December 31, 2021 and 2020, respectively. In addition, the Company had $50,000 and $400,000 in restricted cash as of December 31, 2021 and 2020, respectively, which is reported separately as current assets on the consolidated balance sheet. The Company’s restricted cash consists of cash not available for immediate use that the Company is obligated to maintain in accordance with the terms of its credit card spending arrangement. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows: December 31, 2021 2020 Cash and cash equivalents $ 21,945,981 $ 6,056,190 Restricted cash 50,000 400,000 Total Cash and cash equivalents and Restricted cash $ 21,995,981 $ 6,456,190 Fair Value Measurements The accounting guidance under Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements The Company uses the following fair value hierarchy prescribed by U.S. GAAP, which prioritizes the inputs used to measure fair value as follows: Level 1 Level 2 Level 3 Assets and liabilities are considered to be fair valued on a recurring basis if fair value is measured regularly. However, if the fair value measurement of an instrument does not necessarily result in a change in the amount recorded on the consolidated balance sheets, assets and liabilities are considered to be fair valued on a nonrecurring basis. This typically occurs when accounting guidance requires assets and liabilities to be recorded at the lower of cost or fair value, or on certain nonfinancial assets and liabilities. Nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets, intangible assets, share-based compensation and underwriter warrants measured at fair value upon initial recognition. The carrying amounts of the Company’s cash and cash equivalents, accounts payable and notes payable are reasonable estimates of their fair values due to the short-term nature of these accounts. The fair values of the Company’s share-based compensation and underwriter warrants were based on observable inputs and assumptions used in Black-Scholes valuation models derived from independent external valuations. Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Repair and maintenance costs are expensed as incurred. Depreciation is recorded on a straight-line basis over each asset’s estimated useful life. Property and Equipment Useful life Machinery and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or lease term Automobile 5 years Leases The Company accounts for leases in accordance with ASC 842, Leases Long-Lived Assets and Finite Lived Intangibles The Company has finite lived intangible assets consisting of patents and trademarks. These assets are amortized on a straight-line basis over their estimated remaining economic lives. The patents and trademarks are amortized over 15 years. The Company reviews its long-lived assets and finite lived intangibles for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The events and circumstances the Company monitors and considers include significant decreases in the market price of similar assets, significant adverse changes to the extent and manner in which the asset is used, an adverse change in legal factors or business climate, an accumulation of costs that exceed the estimated cost to acquire or develop a similar asset, and continuing losses that exceed forecasted costs. The Company assesses the recoverability of these assets by comparing the carrying amount of such assets or asset group to the future undiscounted cash flow it expects the assets or asset group to generate. The Company recognizes an impairment loss if the sum of the expected long-term undiscounted cash flows that the long-lived asset is expected to generate is less than the carrying amount of the long-lived asset being evaluated. An impairment charge would then be recognized equal to the amount by which the carrying amount exceeds the fair value of the asset. Income Taxes The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance as of December 31, 2021 and 2020 (see Note 11. Income Taxes). There are no uncertain tax positions that would require recognition in the financial statements. If the Company were to incur an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax would be reported as income taxes. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors. Convertible Preferred Stock The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities Warrants The Company issued to its lead underwriter in the Company’s IPO warrants to purchase up to 140,000 shares of the Company’s common stock. The Company accounts for warrants in accordance with ASC 480, Distinguishing Liabilities from Equity The Company also applied the guidance in ASC 340-10-S99-1, Other Assets and Deferred Costs Stock-based Compensation The Company recognizes the cost of share-based awards granted to employees and directors based on the estimated grant-date fair value of the awards. Cost is recognized on a straight-line basis over the service period, which is generally the vesting period of the award. The Company recognizes stock-based compensation cost and reverses previously recognized costs for unvested awards in the period forfeitures occur. The Company determines the fair value of stock options using the Black-Scholes option pricing model, which is impacted by the fair value of common stock, expected price volatility of common stock, expected term, risk-free interest rates, and expected dividend yield (see Note 9. Stock-based Compensation Expense ) Net Loss Per Share Attributable to Ordinary Shareholders The Company computes loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the shares (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding (see Note 8. Net Loss per Share Attributable to Common Stockholders). Research and Development Expense Research and development expense consist primarily of outsourced engineering services, internal engineering and development expenses, materials, labor and stock-based compensation related to development of the Company’s products and services. Research and development costs are expensed as incurred. Selling, General, and Administrative Expense Selling, general, and administrative expense consist primarily of personnel costs, facilities expenses, depreciation and amortization, travel, and advertising costs. Commitments The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There have been no such liabilities recorded by the Company as of December 31, 2021 and 2020. Segment Reporting The Company’s chief operating decision maker, its Chief Executive Officer, manages operations and business as one operating segment for the purposes of allocating resources, makes operating decisions and evaluates financial performance. Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Recent Accounting Pronouncements There were no significant updates to the recently issued accounting standards. Although there are several other new accounting standards issued or proposed by the Financial Accounting Standards Board (“FASB”), the Company does not believe any of those accounting standards have had or will have a material impact on its financial position or operating results.

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2021
Balance Sheet Components [Abstract]
Balance Sheet Components	3. Balance Sheet Components Property and Equipment, Net Property and equipment is comprised of the following: December 31, December 31, 2021 2020 Automobiles $ 279,617 $ 325,406 Furniture and fixtures 133,102 125,000 Computer and Equipment 76,048 26,157 Property and equipment, gross 488,767 476,563 Less: accumulated depreciation (385,980 ) (342,758 ) Total property and equipment, net $ 102,787 $ 133,805 Depreciation expense for the year ended December 31, 2021 and 2020 was $82,389 and $88,170, respectively. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: December 31, December 31, 2021 2020 Credit card payable $ 11,678 $ 37,455 Accrued expenses 82,478 175,761 Accrued payroll 201,000 94,186 Total accrued expenses and other current liabilities $ 295,156 $ 307,402 On March 27, 2020, the United States Congress passed the Coronavirus, Aid, Relief and Economic Security Act (the “CARES Act”) in response to the economic impact of the coronavirus (“COVID-19”) pandemic in the United States (see Note 13. Risks and Uncertainties). Section 2302 of the CARES Act allowed employers to defer the remittance and payment of the employer’s share of social security taxes that were otherwise required to be remitted between March 27 and December 31, 2020, and to pay the deferred taxes in two installments — with the first half due on December 31, 2021, and the remainder by December 31, 2022. As of December 31, 2021, the Company remitted $67,958 in social security taxes due that were deferred between May 1 and December 31, 2020. Section 2301 of the CARES Act also provided refundable employee retention credits (the “ERC”) against certain employment taxes. The Company is currently evaluating its eligibility to claim the ERC and the impact of the credits on its consolidated statement of operations.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	4. Leases The Company leases its office space under a recurring lease agreement which expired in February 2022 and was subsequently renewed and amended (see Note 14. Subsequent Events). Monthly payments are approximately $15,500 while future minimum payments under the primary terms of the lease in effect at December 31, 2021 are approximately $31,000 in 2022 until the expiration of the lease in February 2022. Rent expense for the year ended December 31, 2021 and 2020 was $236,476 and $229,019, respectively.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	5. Intangible Assets, Net The gross carrying amount and accumulated amortization of separately identifiable intangible assets are as follows: As of December 31, 2021 Gross Accumulated Net Patent $ 7,000 $ (4,083 ) $ 2,917 Trademark 45,000 (17,000 ) 28,000 Total intangible assets $ 52,000 $ (21,083 ) $ 30,917 As of December 31, 2020 Gross Accumulated Net Patent $ 7,000 $ (3,617 ) $ 3,383 Trademark 45,000 (14,000 ) 31,000 Total intangible assets $ 52,000 $ (17,617 ) $ 34,383 Amortization expense for each of the years ended December 31, 2021 and 2020 was $3,466. Estimated amortization expense for all intangible assets subject to amortization in future years is expected to be: Years ended December 31, Amortization 2022 $ 3,467 2023 3,467 2024 3,467 2025 3,467 Thereafter 17,049 Total $ 30,917

Debt

Debt	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt	6. Debt Paycheck Protection Program Notes In April 2020, the Company entered into a Note with JPMorgan Chase (the “Lender”) under the U.S. Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”) established under Section 1102 of the CARES Act, pursuant to which the Company borrowed $695,078 (the “Note”). The Note accrues interest at a rate of 0.98% per annum and matures in 24 months from the date of the Note. The Note may be repaid at any time with no prepayment penalty. All of the funds received under the PPP had been used for qualified purposes. The Company applied for forgiveness of the Note in accordance with PPP guidelines, and in October, 2021, received approval of the forgiveness application. In February 2021, the Company entered into a second Note (the “PPP2 Note”) with the Lender, pursuant to which the Lender agreed to make a loan to the Company under the PPP offered by the SBA in a principal amount of $892,115 pursuant to Title 1 of the CARES Act. The PPP2 Note matures in five years with interest accruing at 0.98% per annum. Proceeds of the PPP2 Note are available to be used to pay for payroll costs, including salaries, commissions, and similar compensation, group health care benefits, and paid leaves; rent; utilities; and interest on certain other outstanding debt. All of the funds received under the PPP2 Note were used for qualified purposes during 2021. The Company applied for forgiveness of the PPP2 Note in accordance with PPP guidelines, and in November, 2021, received approval of the forgiveness application. The PPP and PPP2 Notes that were forgiven by the SBA were recognized as gains and included in ‘Other income’ or the non-operating section of the Company’s consolidated statements of operations.

Capital Structure

Capital Structure	12 Months Ended
	Dec. 31, 2021
Partners' Capital Notes [Abstract]
Capital Structure	7. Capital Structure Common Stock As of December 31, 2021, the Company is authorized to issue 100,000,000 shares with a par value of $0.00001 per share. As of December 31, 2020, the Company was authorized to issue 42,000,000 shares of Common Stock with a par value of $0.00001 per share. As of December 31, 2021 and December 31, 2020, the Company had 26,487,680 and 951,794 shares of Common Stock issued and outstanding, respectively. Holders of common stock have no preemptive, conversion or subscription rights and there is no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that the Company may designate in the future. Convertible Preferred Stock In October 2021, the Company amended its Certificate of Incorporation and revised the number of preferred stock shares authorized for issuance to 10,000,000 shares at a par value of $0.00001. As of December 31, 2021, there were no shares issued and outstanding against these shares. . As of December 31, 2020 and prior to the completion of the IPO, the Company was authorized to issue up to 21,982,491 shares of preferred stock at a par value of $0.00001. Conversion The Company’s convertible preferred stock shares that were outstanding at the completion of the IPO on October 20, 2021 automatically converted to shares of common stock on a 1:1 basis. The authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences prior to the IPO were as follows: Series Shares Shares Per Share Aggregate Gross Series A 10,157,843 10,157,843 0.6842 6,949,996 6,949,996 Series B 6,567,670 6,567,670 3.3939 22,290,015 22,290,015 Series C 5,256,978 5,256,978 15.7933 83,025,031 83,025,031 21,982,491 21,982,491 112,265,042 112,265,042 Warrants As of December 31, 2021, the fair value of the warrants was estimated using the Black-Scholes option-pricing model. The Company used the following assumptions in the model: December 31, 2021 Fair value of underlying securities $ 2.88 Expected volatility 51.0 % Expected term (in years) 5.0 Risk-free interest rate 1.13 % Dividends The holders of preferred stock are entitled to receive dividends, when and if declared by the Company’s Board of Directors, out of any legally available funds. The holders of preferred stock are entitled to receive dividends, prior and in preference to dividends declared on common stock, at the rate of: Series A - $0.0411 per share per annum; Series B - $0.2036 per share per annum; and Series C - $0.9476 per share per annum. Dividends are non-cumulative and will be paid pro rata, on an equal priority, pari passu basis. After payment of preferred stock dividends, any additional dividends will be paid ratably among holders of common stock and preferred stock on an as converted to Common Stock basis. As of December 31, 2021 and 2020, respectively, no dividends have been declared. Voting The holder of each share of Preferred Stock is entitled to voting rights equal to the number of shares of common stock. Preferred stockholders shall cast the number of votes equal to the number of whole shares of common stock into which the shares of Preferred Stock held by such holder are convertible. So long as any shares of Series A Preferred Stock remain outstanding, the holders of the Series A Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. So long as any shares of Series B Preferred Stock remain outstanding, the holders of the Series B Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. So long as any shares of Series C Preferred Stock remain outstanding, the holders of the Series C Preferred Stock, voting as a separate class, are entitled to elect one director of the Company. The holders of Common Stock, voting as a separate class, are entitled to elect two directors of the Company. The holders of Preferred Stock and Common Stock, on an as converted to basis, are entitled to elect any remaining members to the Board of Directors. Liquidation In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of preferred stock on a pari passu basis, are entitled to receive, prior to and in preference over holders of common stock, an amount equal to the original issuance price—Series A - $0.6842 per share; Series B - $3.3939 per share; and Series C - $15.7933 per share. 2) If the assets of the Company available for distribution to its stockholders shall be insufficient to pay the holders of the shares of Preferred Stock the full amount to which they are entitled, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amount which would otherwise be payable in respect to the share of Preferred Stock held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Common Stockholders	8. Net Loss Per Share Attributable to Common Stockholders The following table summarizes the computation of basic and diluted loss per share: Year Ended 2021 2020 Net loss attributable to common stockholders $ (7,799,529 ) $ (8,338,807 ) Basic and diluted weighted average common shares outstanding 5,861,730 949,544 Loss per share: Basic and diluted $ (1.33 ) $ (8.78 ) Basic loss per share is based upon the weighted average number of shares of common stock outstanding during the period. Diluted loss per share would include the effect of unvested restricted stock awards and the convertible preferred Stock; however, such items were not considered in the calculation of the diluted weighted average common shares outstanding since they would be anti-dilutive. Potentially dilutive securities excluded from the calculation of diluted shares outstanding are shown below: Year Ended Year ended 2021 2020 Unvested restricted shares 3,123,931 10,652,680 Common shares issuable upon conversion of preferred stock - 21,982,491 Total 3,123,931 32,635,171

Stock-Based Compensation Expens

Stock-Based Compensation Expense	12 Months Ended
	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation Expense	9. Stock-based Compensation Expense Stock-Based Compensation The Company measures employee and director stock-based compensation awards based on the award’s estimated fair value on the date of grant. Expense associated with these awards is recognized using the straight-line attribution method over the requisite service period for stock options, and is reported in our consolidated statements of comprehensive loss. The fair value of our stock options is estimated, using the Black-Scholes option-pricing model. The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years. Vesting terminates at the end of the employment relationship. Determining the grant date fair value of options requires management to make assumptions and judgments. These estimates involve inherent uncertainties and if different assumptions had been used, stock-based compensation expense could have been materially different from the amounts recorded. The assumptions and estimates for valuing stock options are as follows: ● Fair value per share of Company’s common stock. ● Expected volatility. ● Expected term. ● Risk-free interest rate. ● Estimated dividend yield. Equity Incentive Plans In February 2013, the Board of Directors adopted the 2013 Equity Incentive Plan (“2013 Plan”). The 2013 Plan authorizes the award of stock options, stock appreciation rights, restricted stock awards, stock appreciation rights, RSUs, performance awards, and other stock or cash awards. In October 2021, our Board of Directors adopted the Cyngn Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Our 2021 Plan replaces our 2013 Plan. However, awards outstanding under our 2013 Plan will continue to be governed by their existing terms. As of December 31, 2021 and 2020, approximately 10,502,696 and 9,830,005 shares of common stock were reserved and available for issuance under the 2021 Plan and 2013 Plan, respectively. Options issued under the Plan generally vest based on continuous service provided by the option holder over a four-year period. Compensation expense related to these options is recognized on a straight-line basis over the four-year period based upon the fair value at the grant date. The following table sets forth the summary of options activity for the year ended December 31, 2021 and 2020: Shares Weighted-average exercise Weighted-average remaining Aggregate Outstanding as of December 31, 2020 6,971,301 $ 0.20 7.0 $ 1,399,827 Vested and expected to vest at December 31, 2020 10,892,738 $ 0.54 7.0 $ 5,860,120 Vested and exercisable at December 31, 2020 5,978,428 $ 0.20 7.03 $ 406,094 Granted 2,926,473 3.20 Exercised (41,416 ) 0.23 109,902 Cancelled/forfeited (1,086,664 ) $ 0.20 Outstanding as of December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Vested and expected to vest at December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Vested and exercisable at December 31, 2021 5,645,763 $ 0.27 5.94 $ 14,967,973 The fair value of a stock option is estimated using an option-pricing model that takes into account as of the grant date the exercise price and expected life of the option, the current price of the underlying stock and its expected volatility, expected dividends on the stock, and the risk-free interest rate for the expected term of the option. The Company has used the simplified method in calculating the expected term of all option grants based on the vesting period and contractual term. Compensation costs related to share-based payment transactions are recognized in the financial statements upon satisfaction of the requisite service or vesting requirements. The weighted average per share grant-date fair value of options granted during the years ended December 31, 2021 and 2020 was $2.78 and $0.07 respectively. The following weighted average assumptions were used in estimating the grant date fair values in December 31, 2021 and 2020: December 31, December 31, Fair value of common stock $ 2.78 $ 0.23 Expected term (in years) 6.15 6.00 Risk-free rate 0.95 % 0.68 % Expected volatility 51.0 % 29.34 % Dividend yield 0 % 0 % For the year ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense from stock options of approximately $1,139,247 and $131,732, respectively. As of December 31, 2021, total unrecognized stock-based compensation cost related to outstanding unvested stock options that are expected to vest was $7,031,949. This unrecognized stock-based compensation cost is expected to be recognized over a weighted-average period of approximately 4.6 years. Income tax benefits recognized from stock-based compensation expense recognized for the year ended December 31, 2021 were immaterial due to cumulative losses and valuation allowances.

Retirement Savings Plan

Retirement Savings Plan	12 Months Ended
	Dec. 31, 2021
Retirement Savings Plan [Abstract]
Retirement Savings Plan	10. Retirement Savings Plan Effective November 17, 2017, the Company established the Cyngn Inc. 401(k) Plan for the exclusive benefit of all eligible employees and their beneficiaries with the intention to provide a measure of retirement security for the future. This plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA) and qualifies under Section 401(k) of the Internal Revenue Code. Cyngn, Inc. did not offer and has not provided a company match for its 401(k) Plan.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes For the years ended December 31, 2021 and 2020, the Company recorded income tax expense of $800. The effective tax rate is 0% for the years ended December 31, 2021 and 2020. For financial reporting purposes, the Company’s effective tax rate used for the interim periods is based on the estimated full-year income tax rate. Income tax expense differed from the amount computed by applying the federal statutory income tax rate of 21% to pretax income for the year ended December 31, 2021 as a result of the following: December 31, 2021 Federal tax at statutory rate $ (1,635,786 ) State taxes (543,984 ) Nondeductible expenses (308,449 ) Research and development credit (897,331 ) FIN 48 reserve — Foreign Tax Rate Difference 1,779 Stock Compensation 150,330 True-up and Rate Change 26,751 Valuation allowance 3,207,490 Total $ 800 The tax effects of temporary differences that give rise to significant portions of the Company’s deferred tax assets and liabilities as of December 31, 2021 and 2020 related to the following: December 31, December 31, 2021 2020 Deferred tax assets: Intangibles $ 1,772,704 $ 2,299,275 Net operating losses and Credit carryover 32,425,152 28,834,590 State taxes 168 168 Fixed Assets 89,979 101,694 SBC 243,970 90,726 Accruals And Others 40,005 38,034 Gross deferred tax assets 34,571,977 31,364,488 Valuation allowance (34,571,977 ) (31,364,488 ) Total deferred tax assets - - Deferred tax liabilities: Fixed Assets - - Deferred Commissions - - Total deferred tax liabilities - - Net deferred tax assets: $ - - Management regularly assesses the ability to realize deferred tax assets recorded based upon the weight of available evidence, including such factors as recent earnings history and expected future taxable income on a jurisdiction by jurisdiction basis. In the event that the Company changes its determination as to the amount of realizable deferred tax assets, the Company will adjust its valuation allowance with a corresponding charge to the provision for income taxes in the period in which such determination is made. The Company’s management believes that, based on a number of factors, it is more likely than not, that all or some portion of the deferred tax assets will not be realized; and accordingly, for the years ending December 31, 2021 and December 31, 2020, the Company has provided a valuation allowance against the Company’s U.S. net deferred tax assets. The net change in the valuation allowance for the year ended December 31, 2021 was an increase of $3,207,490. As of December 31, 2021, the Company had net operating loss carryforwards for federal and state income tax purposes of approximately $100,697,360 and $101,454,126, respectively, which will both begin to expire in 2034 As of December 31, 2021, the Company had federal and state research credit carryforwards of approximately $4,258,776 and $2,192,429, respectively. The federal research credit carryforwards will begin to expire in 2023 The Internal Revenue Code of 1986, as amended, imposes restrictions on the utilization of net operating losses in the event of an “ownership change” of a corporation. Accordingly, a company’s ability to use net operating losses may be limited as prescribed under Internal Revenue Code Section 382 (“IRC Section 382”). Events which may cause limitations in the amount of the net operating losses that the Company may use in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. Utilization of the federal and state net operating losses may be subject to substantial annual limitation due to the ownership change limitations provided by the IRC Section 382 and similar state provisions. As of December 31, 2021, and 2020, the total amount of gross unrecognized tax benefits was $1,797,238 and $1,412,668, respectively, including no interest and penalties. As of December 31, 2021, $1,797,238 of the total unrecognized tax benefits, if recognized, would have an impact on the Company’s effective tax rate. The Company estimates that there will be no material changes in its uncertain tax positions in the next 12 months. In accordance with FASB ASC 740, the Company has adopted the accounting policy that interest and penalties recognized are classified as part of its income taxes. Total interest and penalties recognized in the consolidated statement of operations was zero for 2021 and 2020. The Company files income tax returns in the US federal and various state jurisdictions. The Company’s tax years for 2018 and forward are subject to examination by the US tax authorities. The Company’s tax years for 2017 and forward are subject to examination by various state tax authorities. However, due to the fact that the Company had loss and credits carried forward in some jurisdictions, certain items attributable to technically closed years are still subject to adjustment by the relevant taxing authority through an adjustment to tax attributes carried forward to open years. The Company files U.S. and foreign income tax returns with varying statutes of limitations. Due to the Company’s net carryover of unused operating losses, all years remain subject to future examination by tax authorities.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and Contingencies Legal Proceedings The Company is subject to legal and regulatory actions that arise from time to time. The assessment as to whether a loss is probable or reasonably possible, and as to whether such loss or a range of such loss is estimable, often involves significant judgment about future events, and the outcome of litigation is inherently uncertain. There is no material pending or threatened litigation against the Company that remains outstanding as of December 31, 2021 and 2020.

Risks and Uncertainties

Risks and Uncertainties	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Risks and Uncertainties	13. Risks and Uncertainties COVID-19. A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a pandemic by the World Health Organization. While Cyngn’s business has experienced limited disruption due to this pandemic, our leadership team continues to focus on the highest level of safety measures to protect our employees. The Company is aware COVID-19 continues to present significant uncertainty in the future economic outlook for our customers and the markets we serve.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On February 17, 2022, the Company amended the lease agreement (the “Lease Amendment”). The Lease Amendment extended the current lease for an additional 18 months, which commenced on March 1, 2022, and expanded the leased space to a total of 23,311 square feet from the previous 6,886 square feet.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements as of and for the years ended December 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and pursuant to applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The consolidated financial statements include all normal adjustments necessary for a fair presentation of the Company’s financial position at December 31, 2021 and 2020, and operating results and cash flows for the periods presented. These consolidated financial statements should be read in conjunction with the following: i) audited consolidated financial statements as of and for the years ended December 31, 2020 and 2019; ii) the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and’ iii) our final prospectus (the “Prospectus”), filed with the Securities and Exchange Commission or the SEC, pursuant to Rule 424(b) under the Securities Act of 1933, as amended or the Securities Act), on October 21, 2021.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of CYNGN Inc. and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated upon consolidation.
Foreign Currency Translation	Foreign Currency Translation The functional and reporting currency for Cyngn is the U.S. dollar. Monetary assets and liabilities denominated in currencies other than U.S. dollar are translated into the U.S. dollar at period end rates, income and expenses are translated at the weighted average exchange rates for the period and equity is translated at the historical exchange rates. Foreign currency translation adjustments and transactional gains and losses are immaterial to the consolidated financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to underwriter’s warrants and share-based compensation. Estimates are based on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company’s cash is placed with high-credit-quality financial institutions and at times exceeds federally insured limits. The Company has not experienced any credit loss relating to its cash equivalents.
Concentration of Supplier Risk	Concentration of Supplier Risk The Company generally utilizes suppliers for outside development and engineering support. The Company does not believe that there is any significant supplier concentration risk as of December 31, 2021 and 2020.
Cash and Cash Equivalents and Restricted Cash	Cash and Cash Equivalents and Restricted Cash The Company considers all highly liquid money market placements with a remaining maturity of three months or less to be cash equivalents. The Company had $21.9 million and $6.1 million of unrestricted cash and cash equivalents as of December 31, 2021 and 2020, respectively. In addition, the Company had $50,000 and $400,000 in restricted cash as of December 31, 2021 and 2020, respectively, which is reported separately as current assets on the consolidated balance sheet. The Company’s restricted cash consists of cash not available for immediate use that the Company is obligated to maintain in accordance with the terms of its credit card spending arrangement. The following table provides a reconciliation of cash and cash equivalents and restricted cash to amounts shown in the consolidated statements of cash flows: December 31, 2021 2020 Cash and cash equivalents $ 21,945,981 $ 6,056,190 Restricted cash 50,000 400,000 Total Cash and cash equivalents and Restricted cash $ 21,995,981 $ 6,456,190
Fair Value Measurements	Fair Value Measurements The accounting guidance under Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements The Company uses the following fair value hierarchy prescribed by U.S. GAAP, which prioritizes the inputs used to measure fair value as follows: Level 1 Level 2 Level 3 Assets and liabilities are considered to be fair valued on a recurring basis if fair value is measured regularly. However, if the fair value measurement of an instrument does not necessarily result in a change in the amount recorded on the consolidated balance sheets, assets and liabilities are considered to be fair valued on a nonrecurring basis. This typically occurs when accounting guidance requires assets and liabilities to be recorded at the lower of cost or fair value, or on certain nonfinancial assets and liabilities. Nonfinancial assets and liabilities that are measured at fair value on a nonrecurring basis include certain long-lived assets, intangible assets, share-based compensation and underwriter warrants measured at fair value upon initial recognition. The carrying amounts of the Company’s cash and cash equivalents, accounts payable and notes payable are reasonable estimates of their fair values due to the short-term nature of these accounts. The fair values of the Company’s share-based compensation and underwriter warrants were based on observable inputs and assumptions used in Black-Scholes valuation models derived from independent external valuations.
Property and Equipment	Property and Equipment Property and equipment is stated at cost less accumulated depreciation. Repair and maintenance costs are expensed as incurred. Depreciation is recorded on a straight-line basis over each asset’s estimated useful life. Property and Equipment Useful life Machinery and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or lease term Automobile 5 years
Leases	Leases The Company accounts for leases in accordance with ASC 842, Leases
Long-Lived Assets and Finite Lived Intangibles	Long-Lived Assets and Finite Lived Intangibles The Company has finite lived intangible assets consisting of patents and trademarks. These assets are amortized on a straight-line basis over their estimated remaining economic lives. The patents and trademarks are amortized over 15 years. The Company reviews its long-lived assets and finite lived intangibles for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. The events and circumstances the Company monitors and considers include significant decreases in the market price of similar assets, significant adverse changes to the extent and manner in which the asset is used, an adverse change in legal factors or business climate, an accumulation of costs that exceed the estimated cost to acquire or develop a similar asset, and continuing losses that exceed forecasted costs. The Company assesses the recoverability of these assets by comparing the carrying amount of such assets or asset group to the future undiscounted cash flow it expects the assets or asset group to generate. The Company recognizes an impairment loss if the sum of the expected long-term undiscounted cash flows that the long-lived asset is expected to generate is less than the carrying amount of the long-lived asset being evaluated. An impairment charge would then be recognized equal to the amount by which the carrying amount exceeds the fair value of the asset.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Due to the Company’s lack of earnings history, the net deferred tax assets have been fully offset by a valuation allowance as of December 31, 2021 and 2020 (see Note 11. Income Taxes). There are no uncertain tax positions that would require recognition in the financial statements. If the Company were to incur an income tax liability in the future, interest on any income tax liability would be reported as interest expense and penalties on any income tax would be reported as income taxes. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of or changes in tax laws, regulations and interpretations thereof as well as other factors.
Convertible Preferred Stock	Convertible Preferred Stock The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities
Warrants	Warrants The Company issued to its lead underwriter in the Company’s IPO warrants to purchase up to 140,000 shares of the Company’s common stock. The Company accounts for warrants in accordance with ASC 480, Distinguishing Liabilities from Equity The Company also applied the guidance in ASC 340-10-S99-1, Other Assets and Deferred Costs
Stock-based Compensation	Stock-based Compensation The Company recognizes the cost of share-based awards granted to employees and directors based on the estimated grant-date fair value of the awards. Cost is recognized on a straight-line basis over the service period, which is generally the vesting period of the award. The Company recognizes stock-based compensation cost and reverses previously recognized costs for unvested awards in the period forfeitures occur. The Company determines the fair value of stock options using the Black-Scholes option pricing model, which is impacted by the fair value of common stock, expected price volatility of common stock, expected term, risk-free interest rates, and expected dividend yield (see Note 9. Stock-based Compensation Expense )
Net Loss Per Share Attributable to Ordinary Shareholders	Net Loss Per Share Attributable to Ordinary Shareholders The Company computes loss per share attributable to ordinary shareholders by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue shares were exercised into shares. In calculating diluted net loss per share, the numerator is adjusted for the change in the fair value of the shares (only if dilutive) and the denominator is increased to include the number of potentially dilutive common shares assumed to be outstanding (see Note 8. Net Loss per Share Attributable to Common Stockholders).
Research and Development Expense	Research and Development Expense Research and development expense consist primarily of outsourced engineering services, internal engineering and development expenses, materials, labor and stock-based compensation related to development of the Company’s products and services. Research and development costs are expensed as incurred.
Selling, General, and Administrative Expense	Selling, General, and Administrative Expense Selling, general, and administrative expense consist primarily of personnel costs, facilities expenses, depreciation and amortization, travel, and advertising costs.
Commitments	Commitments The Company recognizes a liability with regard to loss contingencies when it believes it is probable a liability has occurred and the amount can be reasonably estimated. If some amount within a range of loss appears at the time to be a better estimate than any other amount within the range, the Company accrues that amount. When no amount within the range is a better estimate than any other amount the Company accrues the minimum amount in the range. There have been no such liabilities recorded by the Company as of December 31, 2021 and 2020.
Segment Reporting	Segment Reporting The Company’s chief operating decision maker, its Chief Executive Officer, manages operations and business as one operating segment for the purposes of allocating resources, makes operating decisions and evaluates financial performance.
Revenue Recognition	Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers
Recent Accounting Pronouncements	Recent Accounting Pronouncements There were no significant updates to the recently issued accounting standards. Although there are several other new accounting standards issued or proposed by the Financial Accounting Standards Board (“FASB”), the Company does not believe any of those accounting standards have had or will have a material impact on its financial position or operating results.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Schedule of reconciliation of cash and cash equivalents and restricted cash to amounts	December 31, 2021 2020 Cash and cash equivalents $ 21,945,981 $ 6,056,190 Restricted cash 50,000 400,000 Total Cash and cash equivalents and Restricted cash $ 21,995,981 $ 6,456,190
Schedule of property and equipment estimated useful life	Property and Equipment Useful life Machinery and equipment 5 years Furniture and fixtures 7 years Leasehold improvements Shorter of 3 years or lease term Automobile 5 years

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2021
Balance Sheet Components [Abstract]
Schedule of property and equipment	December 31, December 31, 2021 2020 Automobiles $ 279,617 $ 325,406 Furniture and fixtures 133,102 125,000 Computer and Equipment 76,048 26,157 Property and equipment, gross 488,767 476,563 Less: accumulated depreciation (385,980 ) (342,758 ) Total property and equipment, net $ 102,787 $ 133,805
Schedule of accrued expenses and other current liabilities	December 31, December 31, 2021 2020 Credit card payable $ 11,678 $ 37,455 Accrued expenses 82,478 175,761 Accrued payroll 201,000 94,186 Total accrued expenses and other current liabilities $ 295,156 $ 307,402

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of gross carrying amount and accumulated amortization of separately identifiable intangible assets	As of December 31, 2021 Gross Accumulated Net Patent $ 7,000 $ (4,083 ) $ 2,917 Trademark 45,000 (17,000 ) 28,000 Total intangible assets $ 52,000 $ (21,083 ) $ 30,917 As of December 31, 2020 Gross Accumulated Net Patent $ 7,000 $ (3,617 ) $ 3,383 Trademark 45,000 (14,000 ) 31,000 Total intangible assets $ 52,000 $ (17,617 ) $ 34,383
Schedule of estimated amortization expense for all intangible assets	Years ended December 31, Amortization 2022 $ 3,467 2023 3,467 2024 3,467 2025 3,467 Thereafter 17,049 Total $ 30,917

Capital Structure (Tables)

Capital Structure (Tables)	12 Months Ended
	Dec. 31, 2021
Partners' Capital Notes [Abstract]
Schedule of authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences	Series Shares Shares Per Share Aggregate Gross Series A 10,157,843 10,157,843 0.6842 6,949,996 6,949,996 Series B 6,567,670 6,567,670 3.3939 22,290,015 22,290,015 Series C 5,256,978 5,256,978 15.7933 83,025,031 83,025,031 21,982,491 21,982,491 112,265,042 112,265,042
Schedule of fair value of the warrants	December 31, 2021 Fair value of underlying securities $ 2.88 Expected volatility 51.0 % Expected term (in years) 5.0 Risk-free interest rate 1.13 %

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Schedule of basic and diluted loss per share	Year Ended 2021 2020 Net loss attributable to common stockholders $ (7,799,529 ) $ (8,338,807 ) Basic and diluted weighted average common shares outstanding 5,861,730 949,544 Loss per share: Basic and diluted $ (1.33 ) $ (8.78 )
Schedule of calculation of diluted shares outstanding	Year Ended Year ended 2021 2020 Unvested restricted shares 3,123,931 10,652,680 Common shares issuable upon conversion of preferred stock - 21,982,491 Total 3,123,931 32,635,171

Stock-Based Compensation Expe_2

Stock-Based Compensation Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Share-Based Payment Arrangement (Tables) [Abstract]
Schedule of stock option	Shares Weighted-average exercise Weighted-average remaining Aggregate Outstanding as of December 31, 2020 6,971,301 $ 0.20 7.0 $ 1,399,827 Vested and expected to vest at December 31, 2020 10,892,738 $ 0.54 7.0 $ 5,860,120 Vested and exercisable at December 31, 2020 5,978,428 $ 0.20 7.03 $ 406,094 Granted 2,926,473 3.20 Exercised (41,416 ) 0.23 109,902 Cancelled/forfeited (1,086,664 ) $ 0.20 Outstanding as of December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Vested and expected to vest at December 31, 2021 8,769,694 $ 1.20 7.15 $ 15,746,916 Vested and exercisable at December 31, 2021 5,645,763 $ 0.27 5.94 $ 14,967,973
Schedule of weighted average fair value of each grant estimated on grant date	December 31, December 31, Fair value of common stock $ 2.78 $ 0.23 Expected term (in years) 6.15 6.00 Risk-free rate 0.95 % 0.68 % Expected volatility 51.0 % 29.34 % Dividend yield 0 % 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of federal statutory income tax	December 31, 2021 Federal tax at statutory rate $ (1,635,786 ) State taxes (543,984 ) Nondeductible expenses (308,449 ) Research and development credit (897,331 ) FIN 48 reserve — Foreign Tax Rate Difference 1,779 Stock Compensation 150,330 True-up and Rate Change 26,751 Valuation allowance 3,207,490 Total $ 800
Schedule of deferred tax assets and liabilities	December 31, December 31, 2021 2020 Deferred tax assets: Intangibles $ 1,772,704 $ 2,299,275 Net operating losses and Credit carryover 32,425,152 28,834,590 State taxes 168 168 Fixed Assets 89,979 101,694 SBC 243,970 90,726 Accruals And Others 40,005 38,034 Gross deferred tax assets 34,571,977 31,364,488 Valuation allowance (34,571,977 ) (31,364,488 ) Total deferred tax assets - - Deferred tax liabilities: Fixed Assets - - Deferred Commissions - - Total deferred tax liabilities - - Net deferred tax assets: $ - -

Description of Business (Detail

Description of Business (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Oct. 22, 2021	Dec. 31, 2021	Dec. 31, 2020
Description of Business (Details) [Line Items]
Common stock, shares authorized (in Shares)		100,000,000	42,000,000
Additional shares of common stock (in Shares)	525,000
Purchase warrants , description	The Purchase Warrants are exercisable six (6) months after the IPO and expire five (5) years thereafter.
Common stock, shares authorized (in Shares)		110,000,000
Common stock shares (in Shares)		100,000,000
Preferred stock shares (in Shares)		10,000,000
Preferred stock, per shares (in Dollars per share)		$ 0.00001
Stock-based compensation expense		$ 1.1
Net losses		7.8	$ 8.3
Accumulated deficit		116.5	108.7
Net cash used in operating activities		8.6	7.9
Unrestricted cash and cash equivalents		21.9	6.1
Liquidity [Member]
Description of Business (Details) [Line Items]
Unrestricted cash and cash equivalents		$ 21.9	$ 6.1
Purchase Warrants [Member]
Description of Business (Details) [Line Items]
Redeemable warrants (in Shares)	140,000
Initial exercise price per share (in Dollars per share)	$ 9.375
IPO [Member]
Description of Business (Details) [Line Items]
Common stock, shares authorized (in Shares)	3,500,000
Offering price per share (in Dollars per share)	$ 7.5
Preferred stock, par value (in Dollars per share)		$ 0.00001
“CYN” [Member] | IPO [Member]
Description of Business (Details) [Line Items]
Net proceeds	$ 23.3

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Summary of Significant Accounting Policies (Details) [Line Items]
Unrestricted cash and cash equivalents	$ 21,900,000	$ 6,100,000
Restricted cash	$ 50,000	$ 400,000
Estimated useful lives	15 years
IPO [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock shares (in Shares)	140,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of cash and cash equivalents and restricted cash to amounts - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of reconciliation of cash and cash equivalents and restricted cash to amounts [Abstract]
Cash and cash equivalents	$ 21,945,981	$ 6,056,190
Restricted cash	50,000	400,000
Total Cash and cash equivalents and Restricted cash	$ 21,995,981	$ 6,456,190

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life	12 Months Ended
	Dec. 31, 2021
Machinery and Equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items]
Property and Equipment, Useful Life	5 years
Furniture and Fixtures [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items]
Property and Equipment, Useful Life	7 years
Leasehold Improvements [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items]
Property and Equipment, Useful Life	Shorter of 3 years or lease term
Automobile [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property and equipment estimated useful life [Line Items]
Property and Equipment, Useful Life	5 years

Balance Sheet Components (Detai

Balance Sheet Components (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Feb. 28, 2021
Balance Sheet Components [Abstract]
Depreciation expense	$ 82,389	$ 88,170
Deferred social security taxes	$ 67,958		$ 892,115

Balance Sheet Components (Det_2

Balance Sheet Components (Details) - Schedule of property and equipment - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of property and equipment [Abstract]
Automobiles	$ 279,617	$ 325,406
Furniture and fixtures	133,102	125,000
Computer and Equipment	76,048	26,157
Property and equipment, gross	488,767	476,563
Less: accumulated depreciation	(385,980)	(342,758)
Total property and equipment, net	$ 102,787	$ 133,805

Balance Sheet Components (Det_3

Balance Sheet Components (Details) - Schedule of accrued expenses and other current liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule of accrued expenses and other current liabilities [Abstract]
Credit card payable	$ 11,678	$ 37,455
Accrued expenses	82,478	175,761
Accrued payroll	201,000	94,186
Total accrued expenses and other current liabilities	$ 295,156	$ 307,402

Leases (Details)

Leases (Details) - USD ($)	Feb. 28, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases (Details) [Line Items]
Future minimum payments		$ 15,500
Rent expense		$ 236,476	$ 229,019
Subsequent Event [Member]
Leases (Details) [Line Items]
Future minimum payments	$ 31,000

Intangible Assets, Net (Details

Intangible Assets, Net (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 3,466	$ 3,466

Intangible Assets, Net (Detai_2

Intangible Assets, Net (Details) - Schedule of gross carrying amount and accumulated amortization of separately identifiable intangible assets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 52,000	$ 52,000
Accumulated Amortization	(21,083)	(17,617)
Net Carrying Amount	30,917	34,383
Patent [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	7,000	7,000
Accumulated Amortization	(4,083)	(3,617)
Net Carrying Amount	2,917	3,383
Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	45,000	45,000
Accumulated Amortization	(17,000)	(14,000)
Net Carrying Amount	$ 28,000	$ 31,000

Intangible Assets, Net (Detai_3

Intangible Assets, Net (Details) - Schedule of estimated amortization expense for all intangible assets - Amortization [Member]	Dec. 31, 2021USD ($)
Intangible Assets, Net (Details) - Schedule of estimated amortization expense for all intangible assets [Line Items]
2022	$ 3,467
2023	3,467
2024	3,467
2025	3,467
Thereafter	17,049
Total	$ 30,917

Debt (Details)

Debt (Details) - USD ($)	Feb. 28, 2021	Apr. 30, 2020	Dec. 31, 2021
Debt Disclosure [Abstract]
Company borrowings		$ 695,078
Interest rate		0.98%
Maturity date	5 years	24 months
Principal amount	$ 892,115		$ 67,958
Interest accruing	0.98%

Capital Structure (Details)

Capital Structure (Details) - $ / shares	Dec. 31, 2021	Oct. 31, 2021	Dec. 31, 2020
Capital Structure (Details) [Line Items]
Preferred stock, shares authorized (in Shares)	100,000,000		42,000,000
Preferred stock, par value	$ 0.00001		$ 0.00001
Common stock, shares issued (in Shares)	26,487,680		951,794
Common stock, shares outstanding (in Shares)	26,487,680		951,794
Convertible Preferred Stock [Member]
Capital Structure (Details) [Line Items]
Convertible preferred stock, shares authorized (in Shares)		10,000,000	21,982,491
Preferred stock, par value		$ 0.00001	$ 0.00001
Series A Preferred Stock [Member]
Capital Structure (Details) [Line Items]
Convertible preferred stock, shares authorized (in Shares)	10,000,000		21,982,491
Preferred stock, par value	$ 0.00001		$ 0.00001
Dividends declared on common stock, per share	0.0411
Original issuance price, per share	$ 0.6842
Series B [Member]
Capital Structure (Details) [Line Items]
Convertible preferred stock, shares authorized (in Shares)	10,000,000		21,982,491
Preferred stock, par value	$ 0.00001		$ 0.00001
Dividends declared on common stock, per share	0.2036
Original issuance price, per share	$ 3.3939
Series C [Member]
Capital Structure (Details) [Line Items]
Convertible preferred stock, shares authorized (in Shares)	10,000,000		21,982,491
Preferred stock, par value	$ 0.00001		$ 0.00001
Dividends declared on common stock, per share	0.9476
Original issuance price, per share	$ 15.7933

Capital Structure (Details) - S

Capital Structure (Details) - Schedule of authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Conversion of Stock [Line Items]
Shares Authorized | shares	21,982,491
Shares Issued and Outstanding | shares	21,982,491
Aggregate Liquidation Amount | $	$ 112,265,042
Gross Proceeds | $	$ 112,265,042
Series A [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	10,157,843
Shares Issued and Outstanding | shares	10,157,843
Per Share Liquidation Preference | $ / shares	$ 0.6842
Aggregate Liquidation Amount | $	$ 6,949,996
Gross Proceeds | $	$ 6,949,996
Series B [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	6,567,670
Shares Issued and Outstanding | shares	6,567,670
Per Share Liquidation Preference | $ / shares	$ 3.3939
Aggregate Liquidation Amount | $	$ 22,290,015
Gross Proceeds | $	$ 22,290,015
Series C [Member]
Conversion of Stock [Line Items]
Shares Authorized | shares	5,256,978
Shares Issued and Outstanding | shares	5,256,978
Per Share Liquidation Preference | $ / shares	$ 15.7933
Aggregate Liquidation Amount | $	$ 83,025,031
Gross Proceeds | $	$ 83,025,031

Capital Structure (Details) -_2

Capital Structure (Details) - Schedule of fair value of the warrants - Warrants [Member]	12 Months Ended
	Dec. 31, 2021USD ($)
Capital Structure (Details) - Schedule of fair value of the warrants [Line Items]
Fair value of underlying securities (in Dollars)	$ 2.88
Expected volatility	51.00%
Expected term	5 years
Risk-free interest rate	1.13%

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted loss per share - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of basic and diluted loss per share [Abstract]
Net loss attributable to common stockholders	$ (7,799,529)	$ (8,338,807)
Basic and diluted weighted average common shares outstanding	5,861,730	949,544
Loss per share:
Basic and diluted	$ (1.33)	$ (8.78)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of calculation of diluted shares outstanding - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of calculation of diluted shares outstanding [Abstract]
Unvested restricted shares	3,123,931	10,652,680
Common shares issuable upon conversion of preferred stock		21,982,491
Total	3,123,931	32,635,171

Stock-Based Compensation Expe_3

Stock-Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Common stock issurance (in Shares)	10,502,696	9,830,005
Fair value of options granted	$ 2.78	$ 0.07
Stock-based compensation expense of stock options	1,139,247	$ 131,732
Stock options expected vest	$ 7,031,949
weighted-average period	4 years 7 months 6 days

Stock-Based Compensation Expe_4

Stock-Based Compensation Expense (Details) - Schedule of stock option	12 Months Ended
	Dec. 31, 2021USD ($)$ / sharesshares
Schedule of stock option [Abstract]
Number of shares, outstanding at beginning balance	6,971,301
Weighted-average exercise price, outstanding at beginning balance (in Dollars per share) | $ / shares	$ 0.2
Weighted-average remaining contractual, outstanding at beginning balance	7 years
Aggregate intrinsic value, outstanding at beginning balance (in Dollars) | $	$ 1,399,827
Number of shares, vested and expected to vest at beginning balance	10,892,738
Weighted-average exercise price, vested and expected to vest at beginning balance (in Dollars per share) | $ / shares	$ 0.54
Weighted-average remaining contractual, vested and expected to vest at beginning balance	7 years
Aggregate intrinsic value, vested and expected to vest at beginning balance (in Dollars) | $	$ 5,860,120
Number of shares, vested and exercisable at beginning balance	5,978,428
Weighted-average exercise price, Vested and exercisable at beginning balance (in Dollars per share) | $ / shares	$ 0.2
Weighted-average remaining contractual, vested and exercisable at beginning balance	7 years 10 days
Aggregate intrinsic value, vested and exercisable at beginning balance (in Dollars) | $	$ 406,094
Number of shares, granted	2,926,473
Weighted-average exercise price, granted (in Dollars per share) | $ / shares	$ 3.2
Number of shares, exercised	(41,416)
Weighted-average exercise price, exercised (in Dollars per share) | $ / shares	$ 0.23
Aggregate intrinsic value, exercised	109,902
Number of shares, cancelled/forfeited	(1,086,664)
Weighted-average exercise price, cancelled/forfeited (in Dollars per share) | $ / shares	$ 0.2
Number of shares, outstanding at ending balance	8,769,694
Weighted-average exercise price, outstanding at ending balance (in Dollars per share) | $ / shares	$ 1.2
Weighted-average remaining contractual, outstanding at ending balance	7 years 1 month 24 days
Aggregate intrinsic value, outstanding at ending balance (in Dollars) | $	$ 15,746,916
Number of shares,vested and expected to vest at ending balance	8,769,694
Weighted-average exercise price, vested and expected to vest at ending balance (in Dollars per share) | $ / shares	$ 1.2
Weighted-average remaining contractual, vested and expected to vest at ending balance	7 years 1 month 24 days
Aggregate intrinsic value, vested and expected to vest at ending balance (in Dollars) | $	$ 15,746,916
Number of shares, vested and exercisable at ending balance	5,645,763
Weighted-average exercise price, Vested and exercisable at ending balance (in Dollars per share) | $ / shares	$ 0.27
Weighted-average remaining contractual, vested and exercisable at ending balance	5 years 11 months 8 days
Aggregate intrinsic value, vested and exercisable at ending balance (in Dollars) | $	$ 14,967,973

Stock-Based Compensation Expe_5

Stock-Based Compensation Expense (Details) - Schedule of weighted average fair value of each grant estimated on grant date - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Schedule of weighted average fair value of each grant estimated on grant date [Abstract]
Fair value of common stock (in Dollars)	$ 2.78	$ 0.23
Expected term (in years)	6 years 1 month 24 days	6 years
Risk-free rate	0.95%	0.68%
Expected volatility	51.00%	29.34%
Dividend yield	0.00%	0.00%

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Taxes (Details) [Line Items]
Income tax expense	$ 800	$ 800
Effective tax rate	0.00%	0.00%
Federal statutory income tax rate	21.00%
Valuation allowance	$ 3,207,490
State income tax expense	168	$ 168
Federal net operating loss carryforward	$ 65,360,163
Net operating losses	1 year
Cumulative ownership, percentage	50.00%
Unrecognized tax benefits	$ 1,797,238	$ 1,412,668
Total unrecognized tax benefit (in Shares)		1,797,238
Tax position term	12 months
Expiration term	2034
Federal [Member]
Income Taxes (Details) [Line Items]
Federal income tax expense	$ 100,697,360
Research credit carryforwards	$ 4,258,776
Expiration term	2023
State [Member]
Income Taxes (Details) [Line Items]
State income tax expense	$ 101,454,126
Research credit carryforwards	$ 2,192,429

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of federal statutory income tax	12 Months Ended
	Dec. 31, 2021USD ($)
Schedule of federal statutory income tax [Abstract]
Federal tax at statutory rate	$ (1,635,786)
State taxes	(543,984)
Nondeductible expenses	(308,449)
Research and development credit	(897,331)
FIN 48 reserve
Foreign Tax Rate Difference	1,779
Stock Compensation	150,330
True-up and Rate Change	26,751
Valuation allowance	3,207,490
Total	$ 800

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of deferred tax assets and liabilities - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Intangibles	$ 1,772,704	$ 2,299,275
Net operating losses and Credit carryover	32,425,152	28,834,590
State taxes	168	168
Fixed Assets	89,979	101,694
SBC	243,970	90,726
Accruals And Others	40,005	38,034
Gross deferred tax assets	34,571,977	31,364,488
Valuation allowance	(34,571,977)	(31,364,488)
Total deferred tax assets
Deferred tax liabilities:
Fixed Assets
Deferred Commissions
Total deferred tax liabilities
Net deferred tax assets:

Subsequent Events (Details)

Subsequent Events (Details)	1 Months Ended
	Feb. 17, 2022
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Subsequent events, description	The Lease Amendment extended the current lease for an additional 18 months, which commenced on March 1, 2022, and expanded the leased space to a total of 23,311 square feet from the previous 6,886 square feet.